These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 10700443)

  • 1. A variant of p22(phox), involved in generation of reactive oxygen species in the vessel wall, is associated with progression of coronary atherosclerosis.
    Cahilly C; Ballantyne CM; Lim DS; Gotto A; Marian AJ
    Circ Res; 2000 Mar; 86(4):391-5. PubMed ID: 10700443
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A prospective study of paraoxonase gene Q/R192 polymorphism and severity, progression and regression of coronary atherosclerosis, plasma lipid levels, clinical events and response to fluvastatin.
    Turban S; Fuentes F; Ferlic L; Brugada R; Gotto AM; Ballantyne CM; Marian AJ
    Atherosclerosis; 2001 Feb; 154(3):633-40. PubMed ID: 11257264
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel polymorphisms in promoter region of atp binding cassette transporter gene and plasma lipids, severity, progression, and regression of coronary atherosclerosis and response to therapy.
    Lutucuta S; Ballantyne CM; Elghannam H; Gotto AM; Marian AJ
    Circ Res; 2001 May; 88(9):969-73. PubMed ID: 11349008
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lipoprotein lipase gene mutations, plasma lipid levels, progression/regression of coronary atherosclerosis, response to therapy, and future clinical events. Lipoproteins and Coronary Atherosclerosis Study.
    Sing K; Ballantyne CM; Ferlic L; Brugada R; Cushman I; Dunn JK; Herd JA; Pownall HJ; Gotto AM; Marian AJ
    Atherosclerosis; 1999 Jun; 144(2):435-42. PubMed ID: 10407505
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interactions between angiotensin-I converting enzyme insertion/deletion polymorphism and response of plasma lipids and coronary atherosclerosis to treatment with fluvastatin: the lipoprotein and coronary atherosclerosis study.
    Marian AJ; Safavi F; Ferlic L; Dunn JK; Gotto AM; Ballantyne CM
    J Am Coll Cardiol; 2000 Jan; 35(1):89-95. PubMed ID: 10636265
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A prospective study of genetic markers of susceptibility to infection and inflammation, and the severity, progression, and regression of coronary atherosclerosis and its response to therapy.
    Elghannam H; Tavackoli S; Ferlic L; Gotto AM; Ballantyne CM; Marian AJ
    J Mol Med (Berl); 2000; 78(10):562-8. PubMed ID: 11199329
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Apolipoprotein E genotypes and response of plasma lipids and progression-regression of coronary atherosclerosis to lipid-lowering drug therapy.
    Ballantyne CM; Herd JA; Stein EA; Ferlic LL; Dunn JK; Gotto AM; Marian AJ
    J Am Coll Cardiol; 2000 Nov; 36(5):1572-8. PubMed ID: 11079660
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of SREBF-1a and SCAP polymorphisms on plasma levels of lipids, severity, progression and regression of coronary atherosclerosis and response to therapy with fluvastatin.
    Salek L; Lutucuta S; Ballantyne CM; Gotto AM; Marian AJ
    J Mol Med (Berl); 2002 Nov; 80(11):737-44. PubMed ID: 12436350
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Lipoprotein and Coronary Atherosclerosis Study (LCAS): design, methods, and baseline data of a trial of fluvastatin in patients without severe hypercholesterolemia.
    West MS; Herd JA; Ballantyne CM; Pownall HJ; Simpson S; Gould L; Gotto AM
    Control Clin Trials; 1996 Dec; 17(6):550-83. PubMed ID: 8974213
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NADH/NADPH oxidase p22 phox C242T polymorphism and lipid peroxidation in coronary artery disease.
    Stanger O; Renner W; Khoschsorur G; Rigler B; Wascher TC
    Clin Physiol; 2001 Nov; 21(6):718-22. PubMed ID: 11722480
    [TBL] [Abstract][Full Text] [Related]  

  • 11. How could a genetic variant of the p22(phox) component of NAD(P)H oxidases contribute to the progression of coronary atherosclerosis?
    Wolin MS
    Circ Res; 2000 Mar; 86(4):365-6. PubMed ID: 10700437
    [No Abstract]   [Full Text] [Related]  

  • 12. Association of NAD(P)H oxidase p22 phox gene variation with advanced carotid atherosclerosis in Japanese type 2 diabetes.
    Hayaishi-Okano R; Yamasaki Y; Kajimoto Y; Sakamoto K; Ohtoshi K; Katakami N; Kawamori D; Miyatsuka T; Hatazaki M; Hazama Y; Hori M
    Diabetes Care; 2003 Feb; 26(2):458-63. PubMed ID: 12547880
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The A640G and C242T p22(phox) polymorphisms in patients with coronary artery disease.
    Zafari AM; Davidoff MN; Austin H; Valppu L; Cotsonis G; Lassègue B; Griendling KK
    Antioxid Redox Signal; 2002 Aug; 4(4):675-80. PubMed ID: 12230880
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of the vascular NADH/NADPH oxidase system in atherosclerosis.
    Yokoyama M; Inoue N; Kawashima S
    Ann N Y Acad Sci; 2000 May; 902():241-7; discussion 247-8. PubMed ID: 10865844
    [TBL] [Abstract][Full Text] [Related]  

  • 15. No association between a genetic variant of the p22(phox) component of NAD(P)H oxidase and the incidence and progression of IgA nephropathy.
    Wolf G; Panzer U; Harendza S; Wenzel U; Stahl RA
    Nephrol Dial Transplant; 2002 Aug; 17(8):1509-12. PubMed ID: 12147803
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Superoxide generation in directional coronary atherectomy specimens of patients with angina pectoris: important role of NAD(P)H oxidase.
    Azumi H; Inoue N; Ohashi Y; Terashima M; Mori T; Fujita H; Awano K; Kobayashi K; Maeda K; Hata K; Shinke T; Kobayashi S; Hirata K; Kawashima S; Itabe H; Hayashi Y; Imajoh-Ohmi S; Itoh H; Yokoyama M
    Arterioscler Thromb Vasc Biol; 2002 Nov; 22(11):1838-44. PubMed ID: 12426213
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NADH/NADPH oxidase p22 phox C242T polymorphism and coronary artery disease in the Australian population.
    Cai H; Duarte N; Wilcken DE; Wang XL
    Eur J Clin Invest; 1999 Sep; 29(9):744-8. PubMed ID: 10469162
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of fluvastatin on coronary atherosclerosis in patients with mild to moderate cholesterol elevations (Lipoprotein and Coronary Atherosclerosis Study [LCAS]).
    Herd JA; Ballantyne CM; Farmer JA; Ferguson JJ; Jones PH; West MS; Gould KL; Gotto AM
    Am J Cardiol; 1997 Aug; 80(3):278-86. PubMed ID: 9264419
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Baseline characteristics of subjects in the Lipoprotein and Coronary Atherosclerosis Study (LCAS) with fluvastatin.
    Herd JA; West MS; Ballantyne C; Farmer J; Gotto AM
    Am J Cardiol; 1994 May; 73(14):42D-49D. PubMed ID: 8198024
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The p22 phox A640G gene polymorphism but not the C242T gene variation is associated with coronary heart disease in younger individuals.
    Gardemann A; Mages P; Katz N; Tillmanns H; Haberbosch W
    Atherosclerosis; 1999 Aug; 145(2):315-23. PubMed ID: 10488959
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.